What Causes Breast Fullness or Swelling?
Many women experience breast fullness or swelling—often described as a “heavy,” “tight,” or “aching” sensation—in the days leading up to menstruation. This symptom, known medically as cyclical mastalg
Many women experience breast fullness or swelling—often described as a “heavy,” “tight,” or “aching” sensation—in the days leading up to menstruation. This symptom, known medically as cyclical mastalgia, is one of the most common manifestations of premenstrual syndrome (PMS) and affects up to 70% of menstruating individuals at some point in their reproductive years.
The underlying mechanism involves hormonal fluctuations during the luteal phase of the menstrual cycle. As estrogen and progesterone levels rise after ovulation—and then decline sharply just before menses—the breast tissue undergoes reversible changes: ductal and lobular epithelial cells proliferate, interstitial fluid accumulates, and connective tissue becomes more edematous. These physiological adaptations prepare the mammary gland for potential lactation but commonly result in transient tenderness, swelling, and increased nodularity that typically resolves within a few days of menstrual onset.
While cyclical breast fullness is almost always benign, clinicians advise patients to monitor for red flags—including unilateral swelling without cyclical pattern, persistent localized pain, skin changes (e.g., dimpling, erythema, peau d’orange), nipple discharge (especially if bloody or spontaneous), or palpable masses that do not fluctuate with the cycle. Such findings warrant prompt clinical evaluation to rule out conditions such as fibroadenoma, cyst formation, infection (mastitis), or, rarely, malignancy.
Lifestyle modifications—including reduced caffeine and sodium intake, regular aerobic exercise, and well-fitted supportive bras—can alleviate discomfort for many. In moderate-to-severe cases, nonsteroidal anti-inflammatory drugs (NSAIDs) or topical diclofenac gel may be recommended. Hormonal interventions are generally avoided unless symptoms are refractory and significantly impair quality of life, given their risk-benefit profile.